Vnitr Lek 2016, 62(Suppl 4):85-93

Short-term and long-term glycemic variability and its relationship to microvascular complications of diabetes

Martin Prázný*, Jan ©krha, Jan ©oupal, Jan ©krha jr
III. interní klinika 1. LF UK a VFN v Praze

Vascular complications of diabetes result from long lasting unsatisfactory glycemic control. We usually assess glycemic control based on the value of glycated hemoglobin HbA1c. The glycated hemoglobin test, however, says nothing about short-term glycemic fluctuations. Recently, continuous monitoring of glycemia has enabled us an in-depth assessment of changes in glucose concentrations, called glycemic variability. In connection with the research into short-term glycemic variability, also the study of long-term fluctuations in glycemic control based on HbA1c variability has now intensified. Glycemic variability may be related to oxidation stress, endothelial dysfunction and inflammation, the factors traditionally associated with vascular damage. Several studies have described the relation of glycemic variability to macrovascular complications of diabetes, still its relation to microvascular complications remains unclear. This overview summarizes the recent findings in the field of glycemic variability and its possible association with retinopathy, nephropathy and neuropathy.

Keywords: type 1 and 2 diabetes mellitus; glycemic variability; microvascular complications; HbA1c - variability

Received: September 4, 2016; Accepted: October 13, 2016; Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prázný M, ©krha J, ©oupal J, ©krha J. Short-term and long-term glycemic variability and its relationship to microvascular complications of diabetes. Vnitr Lek. 2016;62(Supplementum 4):85-93.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nathan DM, McGee P, Steffes MW et al. Relationship of glycated albumin to blood glucose and HbA(1c) values and to retinopathy, nephropathy and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014; 63(1): 282-290. Dostupné z DOI: <http://dx.doi.org/10.2337/db13-0782>. Go to original source... Go to PubMed...
    2. Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci 2014; 15(10): 18381-18406. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms151018381>. Go to original source... Go to PubMed...
    3. Brownlee M. The pathobiology of diabetic complications - a unifying mechanism. Diabetes 2005; 54(6): 1615-1625. Go to original source... Go to PubMed...
    4. El-Osta A, Brasacchio D, Yao DC et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205(10): 2409-2417. Dostupné z DOI: <http://dx.doi.org/10.1084/jem.20081188>. Erratum in J Exp Med 2008; 205(11): 2683. Go to original source... Go to PubMed...
    5. Salisbury D, Bronas U. Reactive oxygen and nitrogen species. Impact on endothelial dysfunction. Nurs Res 2015; 64(1): 53-66. Dostupné z DOI: <http://dx.doi.org/10.1097/NNR.0000000000000068>. Go to original source... Go to PubMed...
    6. Wang L, Wang J, Fang J et al. High glucose induces and activates Toll-like receptor 4 in endothelial cells of diabetic retinopathy. Diabetol Metab Syndr 2015; 7: 89. Dostupné z DOI: <http://dx.doi.org/10.1186/s13098-015-0086-4>. Go to original source... Go to PubMed...
    7. De NigrisV, Pujadas G, La Sala L et al. Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovasc Diabetol 2015; 14: 114. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933-015-0278-0>. Go to original source... Go to PubMed...
    8. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681-1687. Go to original source... Go to PubMed...
    9. Zhang XG, Zhang YQ, Zhao DK et al. Relationship between blood glucose fluctuation and macrovascular endothelial dysfunction in type 2 diabetic patients with coronary heart disease. Eur Rev Med Pharmacol Sc 2014; 18(23): 3593-3600.
    10. Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57(5): 1349-1354. Dostupné z DOI: <http://dx.doi.org/10.2337/db08-0063>. Go to original source... Go to PubMed...
    11. Schisano B, Tripathi G, McGee K et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011; 54(5): 1219-1226. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-011-2049-0>. Go to original source... Go to PubMed...
    12. Pena AS, Couper JJ, Harrington J et al. Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. Diabetes Technol Ther 2012; 14(6): 457-462. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2011.0229>. Go to original source... Go to PubMed...
    13. Ceriello A, Novials A, Ortega E et al. Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutr Metab Cardiovasc Dis 2014; 24(2): 116-123. Dostupné z DOI: <http://dx.doi.org/10.1016/j.numecd.2013.05.003>. Go to original source... Go to PubMed...
    14. Kumar B, Kowluru A, Kowluru RA. Lipotoxicity augments glucotoxicity-induced mitochondrial damage in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2015; 56(5): 2985-2992. Dostupné z DOI: <http://dx.doi.org/10.1167/iovs.15-16466>. Go to original source... Go to PubMed...
    15. Yang HK, Kang B, Lee SH et al. Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes. J Diabetes Complicat 2015; 29(6): 776-782. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2015.04.008>. Go to original source... Go to PubMed...
    16. Chang CH, Chuang LM. Glycated hemoglobin variability and retinopathy progression in type 1 diabetes: is month-to-month instability a better predictor? J Diabetes Investig 2014; 5(2): 149-152. Dostupné z DOI: <http://dx.doi.org/10.1111/jdi.12147>. Go to original source... Go to PubMed...
    17. Cheng DS, Fei Y, Liu Y et al. HbA1c variability and the risk of renal status progression in diabetes mellitus: a meta-analysis. PLoS One 2014; 9(12): e115509. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0115509>. Go to original source... Go to PubMed...
    18. Kohnert KD, Heinke P, Vogt L et al. Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes 2015; 6(1): 17-29. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v6.i1.17>. Go to original source... Go to PubMed...
    19. Service FJ. Glucose variability. Diabetes 2013; 62(5): 1398-1404. Dostupné z DOI: <http://dx.doi.org/10.2337/db12-1396>. Go to original source... Go to PubMed...
    20. Saisho Y, Tanaka C, Tanaka K et al. Relationships among different glycemic variability indices obtainedby continuous glucose monitoring. Primary Care Diabetes 2015; 9(4): 290-296. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pcd.2014.10.001>. Go to original source... Go to PubMed...
    21. Fabris C, Facchinetti A, Sparacino G et al. Glucose variability indices in Type 1 diabetes: parsimonious set of indices revealed by Sparse Principal Component Analysis. Diabetes Technol Ther 2014; 16(10): 644-652. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0252>. Go to original source... Go to PubMed...
    22. Selvin E, Rawlings AM, Grams M et al. Association of 1,5-anhydroglucitolwith diabetes and microvascular conditions. Clin Chem 2014; 60(11): 1409-1418. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2014.229427>. Go to original source... Go to PubMed...
    23. Ceriello A, Novials A, Ortega E et al. Vitamin C further improves the protective effect of glucagonlike peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in Type 1 diabetes. Diabetes Care 2013; 36(12): 4104-4108. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13-0750>. Erratum in Diabetes Care 2014; 37(7): 2063. Go to original source... Go to PubMed...
    24. Yousetzade G, Nakhaee A. Insulin-induced hypoglycemia and stress oxidative state in healthy people. Acta Diabetol 2012; 49(Suppl 1): S81-S85. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592-011-0311-z>. Go to original source... Go to PubMed...
    25. Wang JL, Alexanian A, Ying R et al. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochontrial oxidative stress role for AMP kinase. Arterioscler Thromb Vasc Biol 2012; 32(3): 712-720. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.111.227389>. Go to original source... Go to PubMed...
    26. Jaiswal M, McKeon K, Comment N et al. Association between impaired cardiovascular autonomic function and hypoglycemia in patients with Type 1 diabetes. Diabetes Care 2014; 37(9): 2616-2621. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-0445>. Go to original source... Go to PubMed...
    27. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015; 38(8): 1610-1614. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-2898>. Go to original source... Go to PubMed...
    28. Rodbard D. Evaluating quality of glycemic control: graphical displays of hypo- and hyper-glycemia, time in target range, and mean glucose. J Diabetes Sci Technol 2015; 9(1): 56-62. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296814551046>. Go to original source... Go to PubMed...
    29. Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36(Suppl 2): S272-S275. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS13-2030>. Go to original source... Go to PubMed...
    30. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015; 38(8): 1615-1621. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-0099>. Go to original source... Go to PubMed...
    31. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35(9): 1814-1816. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12-0749>. Go to original source... Go to PubMed...
    32. Niskanen L, Virkamäki A, Hansen JB et al. Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 2009; 86(2): e15-e18. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2009.08.005>. Go to original source... Go to PubMed...
    33. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008; 14(6): 750-756. Go to original source... Go to PubMed...
    34. Smith-Palmer J, Brändle M, Trevisan R et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 2014; 105(3): 273-284. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2014.06.007>. Go to original source... Go to PubMed...
    35. ©oupal J, ©krha J Jr, Fajmon M et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014; 16(4): 198-203. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0205>. Go to original source... Go to PubMed...
    36. Lachin JM, Genuth S, Nathan DM et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial revisited. Diabetes 2008; 57(4): 995-1001. Dostupné z DOI: <http://dx.doi.org/10.2337/db07-1618>. Go to original source... Go to PubMed...
    37. Gorst C, Kwak CS, AslamS et al. Long-term glycemic variability and risk of adverse outcomes:a systematic review and meta-analysis. Diabetes Care 2015; 38(12): 2354-2369. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-1188>. Go to original source... Go to PubMed...
    38. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29(7): 1486-1490. Go to original source... Go to PubMed...
    39. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008; 31(11): 2198-2202. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08-0864>. Go to original source... Go to PubMed...
    40. Hermann JM, Hammes HP, Rami-Mehar B et al. HbA1c variability as an independent risk factor for diabetic retinopathy in Type 1 diabetes: A German/Austrian multicenter analysis on 35,891 patients. PLoS One 2014; 9(3): e91137. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0091137>. Go to original source... Go to PubMed...
    41. Hietala K, Waden J, Forsblom C et al. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia 2013; 56(4): 737-745. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-012-2816-6>. Go to original source... Go to PubMed...
    42. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B et al. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complicat 2003; 17(2): 78-81. Go to original source... Go to PubMed...
    43. Zoppini G, Verlato G, Targher G et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis 2009; 19(5): 334-339. Dostupné z DOI: <http://dx.doi.org/10.1016/j.numecd.2008.02.007>. Go to original source... Go to PubMed...
    44. Hirakawa Y, Arima H, Zoungas S et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014; 37(8): 2359-2365. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-0199>. Go to original source... Go to PubMed...
    45. Takao T, Ide T, Yanagisawa H et al. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract 2010; 89(3): 296-302. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2010.03.027>. Go to original source... Go to PubMed...
    46. Takao T, Ide T, Yanagisawa H et al. The effects of fasting plasma glucose variability and time dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 2011; 91(2): e40-e42. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2010.10.009>. Go to original source... Go to PubMed...
    47. Nazim J, Fendler W, Starzyk J. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes. Endokrynol Pol 2014; 65(2): 83-89. Dostupné z DOI: <http://dx.doi.org/10.5603/EP.2014.0012>. Go to original source... Go to PubMed...
    48. Jin SM, Kim TH, Baek SOJ et al. Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring. Diabet Med 2015; 32(2): 274-279. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12607>. Go to original source... Go to PubMed...
    49. Hou X, Wang C, Wang S et al. Fluctuation between fasting and 2-H postload glucose state is associated with glomerular hyperfiltration in newly diagnosed diabetes patients with HbA1c, 7%. PLoS One 2014; 9(10):e111173. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0111173>. Go to original source... Go to PubMed...
    50. Hsu CC, Chang HY, Huang MC et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia 2012; 55(12): 3163-3172. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-012-2700-4>. Go to original source... Go to PubMed...
    51. Penno G, Solini A, Bonora E et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes. The Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2013; 36(8): 2301-2310. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12-2264>. Go to original source... Go to PubMed...
    52. Bragd J, Adamson U, Bäcklund LB et al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008; 34(6 Pt 1): 612-616. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2008.04.005>. Go to original source... Go to PubMed...
    53. Sharma D, Morrison G, Joseph F et al. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 2011; 54(11): 2768-2770. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-011-2282-6>. Go to original source... Go to PubMed...
    54. Samsom M, Akkermans LM, Jebbink RJ et al. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40(5): 641-646. Go to original source... Go to PubMed...
    55. Bellastella G, Maiorino MI, Olita L et al. Premature ejaculation is associated with glycemic control in Type 1 diabetes. J Sex Med 2015; 12(1): 93-99. Dostupné z DOI: <http://dx.doi.org/10.1111/jsm.12755>. Go to original source... Go to PubMed...
    56. Iwasaki S, Kozawa J, Fukui K et al. Coefficient of variation of R-R interval closely correlates with glycemic variability assessed by continuous glucose monitoring in insulin-depleted patients with type 1 diabetes. Diab Res Clin Pract 2015; 109(2): 397-403. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2015.05.021>. Go to original source... Go to PubMed...
    57. Xu F, Zhao L, Su J et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabet Metab Syndr 2014; 6(1): 139. Dostupné z DOI: <http://dx.doi.org/10.1186/1758-5996-6-139>. Go to original source... Go to PubMed...
    58. Jun JE, Jin SM, Baek J et al. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14: 70. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933-015-0233-0>. Go to original source... Go to PubMed...
    59. Martín-Cora FJ, Fornal CA, Metzler CW et al. Insulin induced hypoglycemia decreases single-unit activity of serotonergic medullary raphe neurons in freely moving cats: relationship to sympathetic and motor output. Eur J Neurosci 2002; 16(4): 722-734. Go to original source... Go to PubMed...
    60. Hsu CR, Chen YT, Sheu WH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complicat 2015; 29(2): 302-306. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2014.11.013>. Go to original source... Go to PubMed...
    61. Probstfield JL, Hirsch I, O'Brien K et al. [The FLAT-SUGAR Trial investigators]. Design of FLAT-SUGAR: Randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk Type 2 diabetes. Diabetes Care 2015; 38(8): 1558-1566. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-2689>. Go to original source... Go to PubMed...
    62. Kuricová K, Pácal L, ©oupal J et al. Effect of glucose variability on pathways associated with glucotoxicity in diabetes: Evaluation of a novel in vitro experimental approach. Diabetes Res Clin Pract 2016; 114: 1-8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2016.02.006>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.